Source Multiple Sclerosis News Today: A new study demonstrates that intracellular sigma peptide (ISP) can promote remyelination in a mouse model of multiple sclerosis (MS).
Source Multiple Sclerosis News Today: The National Stem Cell Foundation (NSCF) announced the start of a pioneering project to investigate the impact of microgravity on the neurodegeneration associated with primary progressive multiple sclerosis (PPMS) and Parkinson’s disease.
Source BioSpace: Multiple sclerosis (MS) is an often-disabling disease of the central nervous system caused by damage to the myelin coating around the nerves.
Scientists have discovered that a specific brain cell known as a 'projection neuron' has a central role to play in the brain changes seen in multiple sclerosis (MS).
Source Science Daily: The research shows that projection neurons are damaged by the body's own immune cells and that this damage could underpin the brain shrinkage and cognitive changes associated with MS. These new findings provide a platform for specific new MS therapies that target damaged brain cells to be developed.
Source Medical News Toady: A Phase 3 trial is planned to confirm the safety and efficacy of oral ibudilast (MN-166) in treating people with secondary progressive multiple sclerosis (SPMS) without relapses or those whose disease is not active, MediciNova announced.
Source Multiple Sclerosis News Today: A first group of healthy volunteers in a Phase 1 trial assessing the safety and tolerability of T20K, Cyxone‘s plant protein-derived candidate for the treatment of multiple sclerosis(MS), has been dosed in a study taking place in The Netherlands, the company announced.
Source Neurology Advisor: For patients with progressive multiple sclerosis, a diet-induced lipid profile change improved fatigue, according to a study published in PLoS One.
Since 8th June 2019, Steve Barnes, who regularly attends the Berkshire MS Therapy Centre, has been travelling to Canterbury each week to be involved in the medical trial using a robotic suit to exercise:
Source MS Trust: A recent review has outlined the progress made so far in understanding the biology of remyelination, what goes wrong in MS, some of the research problems that need to be tackled and the prospect for treatments in the not-too-distant future.